Related Experiment Video
Updated: Jun 17, 2025
Renal Ischaemia Reperfusion Injury: A Mouse Model of Injury and Regeneration
Published on: June 7, 2014
Reconstituted HDL ameliorated renal injury of diabetic kidney disease in mice
Yu Tao1, Andras G Lacko1, Nirupama A Sabnis1
1Department of Physiology and Anatomy, University of North Texas Health Science Center, Fort Worth, Texas, USA.
Insights
Reconstituted high-density lipoprotein (rHDL) shows promise in treating diabetic kidney disease (DKD). This study found rHDL treatment significantly reduced kidney injury, fibrosis, and podocyte loss in a mouse model of DKD.
Area of Science:
- Nephrology
- Cardiovascular Research
- Biomedical Engineering
Background:
- Diabetic kidney disease (DKD) is a major complication of diabetes, characterized by progressive renal injury and lack of effective treatments.
- Endothelial nitric oxide synthase (eNOS) deficiency exacerbates DKD, highlighting its role in disease pathogenesis.
- Reconstituted high-density lipoprotein (rHDL) has shown potential therapeutic benefits in various conditions.
Purpose of the Study:
- To investigate the renoprotective effects of reconstituted high-density lipoprotein (rHDL) in a mouse model of diabetic kidney disease (DKD).
- To evaluate the impact of rHDL on kidney function, histological damage, and specific molecular markers in eNOS-deficient diabetic mice.
Main Methods:
- Utilized eNOS knockout (eNOS-/-) dbdb mice, a model for DKD, alongside wild-type controls.
- Administered rHDL nanoparticles intravenously to diabetic mice for four weeks.
- Assessed kidney injury through measurements of albuminuria, glomerular filtration rate (GFR), histological analysis, and Western blot/immunohistochemical examination of fibronectin and collagen IV.
Main Results:
- rHDL treatment significantly attenuated the decline in GFR and reduced albuminuria in diabetic mice.
- Histological examination revealed that rHDL alleviated glomerular injury, renal fibrosis, and podocyte loss.
- rHDL administration led to a significant reduction in the elevated protein levels of fibronectin and collagen IV in the renal cortex.
Conclusions:
- Reconstituted high-density lipoprotein (rHDL) demonstrates significant renoprotective effects in a mouse model of diabetic kidney disease.
- rHDL ameliorates key pathological features of DKD, including glomerular injury, fibrosis, and podocyte damage.
- These findings suggest that rHDL could be a potential therapeutic strategy for managing diabetic kidney disease.
Abstract:
Diabetic kidney disease (DKD) is a devastating kidney disease and lacks effective therapeutic interventions. The present study was aimed to determine whether reconstituted high-density lipoprotein (rHDL) ameliorated renal injury in eNOS-/- dbdb mice, a mouse model of DKD. Three groups of mice, wild type C57BLKS/J (non-diabetes), eNOS-/- dbdb (diabetes), and eNOS-/- dbdb treated with rHDL (diabetes+rHDL) with both males and females were used. The rHDL nanoparticles were administered to eNOS-/- dbdb mice at Week 16 at 5 μg/g body weight in ~100 μL of saline solution twice per week for 4 weeks via retroorbital injection. We found that rHDL treatment significantly blunted progression of albuminuria and GFR decline observed in DKD mice. Histological examinations showed that the rHDLs significantly alleviated glomerular injury and renal fibrosis, and inhibited podocyte loss. Western blots and immunohistochemical examinations showed that increased protein abundances of fibronectin and collagen IV in the renal cortex of eNOS-/- dbdb mice were significantly reduced by the rHDLs. Taken together, the present study suggests a renoprotective effect of rHDLs on DKD.
